提高胃肠胰腺神经内分泌肿瘤的诊断率——胃肠激素临床研究进展  

Promote the Diagnosis Rate of Gastroenteropancreatic Neuroendocrine Tumors: Advances in Clinical Study of Gut Hormones

作　　者：钱家鸣[1] 李景南[1] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院消化内科,100730

出　　处：《胃肠病学》2008年第4期193-194,共2页Chinese Journal of Gastroenterology

摘　　要：胃肠胰腺神经内分泌肿瘤(GEP-NETs)是少见病,且诊断难度大。随着各种生化、影像以及内镜检查技术的发展,其诊断率不断提高。嗜铬粒蛋白A作为GEP-NETs的"通用"肿瘤标志物,其诊断敏感性和特异性为70%～95%。生长抑素受体显像大大提高了肿瘤的定位诊断率和鉴别诊断;内镜超声技术的应用将进一步提高直径<1cm肿瘤的定位,结合术中超声技术可进一步提高GEP-NETs的定位诊断。针对上述诊断技术不敏感的GEP-NETs,随着对肿瘤胃肠激素研究的进展,将有望开发出更多特异性或敏感性高的诊断方法。Gastroenteropancreatic neuroendocrine tumors （GEP-NETs） are rare diseases, and are difficult in diagnosis. Recently, due to the advances in biochemical, imaging and endoscopic diagnostic techniques, diagnosis rate has been gradually increased. Chromogranin A （CgA） as the ＂common＂ tumor marker of GEP-NETs, has a diagnostic sensitivity and specificity between 70%-95%. Somatostatin receptor imaging has improved greatly the localization and differentiation of the tumors. With endoscopic uhrasonography one can visualize a tumor less than 1 cm. Combined with intraoperative uhrasonography it could further increase the localization of tumor. In the future, more specific and sensitive diagnostic methods may be developed with the advances in the study of GEP-NETs.

关 键 词：胃肠道 癌 神经内分泌 诊断 

分 类 号：R735[医药卫生—肿瘤]